NCM · Financial Statements
Phio Pharmaceuticals Corp. (PHIO) Financial Statements
$0.98
NCM: PHIO
Market Cap $11.37M
Overview Financials Dividend
Phio Pharmaceuticals Corp. most recently reported annual revenue of $0, a net loss of $9.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $0 $0 $0 Operating Profit $-14.0M $-11.0M $-11.0M $-7.0M $-9.0M Net Profit $-13.0M $-11.0M $-11.0M $-7.0M $-9.0M EPS $-111.32 $-89.61 $-46.76 $-0.91 $-1.45 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $25.0M $13.0M $9.0M $6.0M $21.0M Total Liabilities $3.0M $2.0M $2.0M $1.0M $1.0M Cash $24.0M $12.0M $8.0M $5.0M $21.0M Borrowings $0 $0 $0 $0 $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-12.0M $-12.0M $-11.0M $-7.0M $-8.0M Investing Cash Flow $0 $0 $0 $0 $0 Financing Cash Flow $2.0M $0 $0 $0 $0 Net Cash Flow $10.0M $-12.0M $-3.0M $-3.0M $16.0M Free Cash Flow $-12.0M $-12.0M $-11.0M $-7.0M $-8.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.01 EV / EBITDA 0.12 FCF Yield -106.68% Quick Ratio 15.87 Interest Coverage — Return 1Y -62.60% Return 3Y -96.38% Return 5Y -99.55%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .